Pulse Biosciences director receives 50,792 stock options at $16.16
Rhea-AI Filing Summary
Pulse Biosciences director and 10% owner Robert W. Duggan received two stock option grants on 08/15/2025 totaling 50,792 options to buy common stock at an exercise price of $16.16 per share. One option for 30,000 shares vests monthly over one year beginning 09/15/2025. The second option for 20,792 shares vests quarterly over one year beginning 09/05/2025. Both options expire 08/15/2035. The Form 4 was filed as a single reporting person filing and signed by an attorney-in-fact on 08/19/2025.
Positive
- Time-based vesting aligns the reporting person’s interests with the company by requiring continued service to realize value
- Clear disclosure of grant amounts, exercise price ($16.16), vesting commencement dates, and expiration (08/15/2035) enhances transparency
Negative
- Potential dilution if 50,792 options are exercised, which could modestly reduce existing shareholders’ ownership (absolute impact not provided)
- No information in this filing about the company’s total outstanding shares or market capitalization, so materiality cannot be quantified
Insights
TL;DR: Director received time-based options totaling 50,792 shares at $16.16, creating potential future dilution but aligning incentives.
The grants are time-based and vest over one year, which ties the director’s compensation to continued service rather than immediate sale. The exercise price of $16.16 establishes the economic entry point for share purchase; materiality depends on company market cap and outstanding shares, which are not provided here. This filing reports routine insider compensation rather than a change in control or secondary sale.
TL;DR: These awards follow standard equity compensation patterns for executives/directors with staged vesting to retain leadership.
The staggered monthly and quarterly vesting schedules indicate retention-focused design. The director is also a 10% owner, so the grants may affect his overall ownership percentage modestly upon exercise. The Form 4 discloses execution and expiration dates clearly and was timely signed by an attorney-in-fact.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 30,000 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 20,792 | $0.00 | -- |
Footnotes (1)
- The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 15, 2025. The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2025.
